ROCKVILLE, MD and SHENZHEN, CHINA, October 20, 2023— HighTide Therapeutics, Inc. (“HighTide”), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic and digestive diseases, today announced the company's Chief Development Officer, Leigh MacConell, Ph.D., will present at the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023.

The H.C. Wainwright conference will include presentations by key opinion leaders in the field of nonalcoholic fatty liver disease (NAFLD). The conference is being held virtually and is accessible via https://hcwevents.com/nashconference/.

About HighTide 

HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC.  In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

For more information, please visit www.hightidetx.com

Contact: pr@hightidetx.com.